Navigation Links
Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
Date:7/25/2011

PRINCETON, N.J. , July 25, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended June 30, 2011.

Financial ResultsRevenues were $0.2 million during the quarter ended June 30, 2011 compared to $0.2 million for the quarter ended June 30, 2010 and include amortization of up-front and subsequent collaborative and license payments received from Roche.

Net cash used in operating activities during the three months ended June 30, 2011 was $22.3 million. Pharmasset held $188.2 million in cash and cash equivalents as of June 30, 2011.

Total operating expenses for the quarter ended June 30, 2011 were $22.6 million as compared to $15.7 million for the same period in 2010.

Pharmasset reported a net loss of $22.6 million, or $0.60 per share, for the quarter ended June 30, 2011, as compared to a net loss of $16.0 million, or $0.50 per share, for the quarter ended June 30, 2010.

Recent Operational Highlights:-- Bristol-Myers Squibb initiated a combination trial with BMS-790052 and PSI-7977

-- Completed enrollment of ELECTRON's original four arms with PSI-7977

-- Expanded the ELECTRON trial with the addition of three new treatment arms

-- We were granted a US patent (US patent 7,964,580) titled 'Nucleoside Phosphoramidate Prodrugs' covering PSI-7977

-- Pharmasset and Tibotec announced a clinical collaboration to combine PSI-7977 and Tibotec's TMC435, a protease inhibitor

-- Reported SVR24 data from PROTON trial with PSI-7977 in genotype 2 or 3 patients

-- Roche disclosed that it expects to file, in 2014, an application for marketing approval of mericitabine

"Pharmasset had a very successful first half of 2011 with a strong showing at the EASL meeting, the signing of a clinical collaboration with Tibotec and the issuance of a US patent for PSI-7977," stated Schaefer Price, President and Chief Executive Officer. "The second half of 2011 holds a number of important clinical milestones for us, as we plan to report SVR12 data from both the PROTON and ELECTRON trials. In addition, we plan to initiate the QUANTUM study, our first SVR-focused, interferon free trial with PSI-7977 and PSI-938 in the third quarter."

Calendar Year 2011 Anticipated Milestones:-- Report SVR12 data from PROTON trial with PSI-7977 in genotype 1 patients in second half 2011

-- Report SVR12 data from ELECTRON trial with PSI-7977 in genotype 2 or 3 patients in second half 2011

-- Initiate QUANTUM trial with PSI-7977 and PSI-938 in third quarter 2011

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates advancing in trials in various populations. Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently under study in four Phase 2b trials in patients with HCV genotypes 1 through 6, including abbreviated duration interferon and interferon-free regimens. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, recently reported safety and efficacy data from 14 days of monotherapy as well as 14 days in combination with the pyrimidine, PSI-7977. An SVR-endpoint study of the purine-pyrimidine combination is anticipated to begin in the third quarter of 2011. Mericitabine (RG7128) continues in three Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice +1 (609) 865-0693 Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.

PHARMASSET, INC.CONDENSED STATEMENTS OF OPERATIONS(UNAUDITED)(in thousands, except share and per share amounts)Three Months EndedNine Months EndedJune 30,June 30,2011201020112010Revenues

$
246$
249$
739$
769COSTS AND EXPENSES:  Research and development

18,91711,50554,68032,731  General and administrative

3,7194,20012,56712,086Total costs and expenses

22,63615,70567,24744,817Operating loss

(22,390)(15,456)(66,508)(44,048)Investment income

4186Other income

--489-Interest expense

(219)(565)(927)(1,909)Loss before income taxes

(22,605)(16,020)(66,938)(45,951)Provision (benefit) for income taxes

--(973)-Net loss

$
(22,605)$
(16,020)$
(65,965)$
(45,951)Net loss per share: basic and diluted

$
(0.60)$
(0.50)$
(1.84)$
(1.54)Weighed average shares outstanding:basic and diluted

37,435,61432,000,52835,937,45629,932,398PHARMASSET, INC.BALANCE SHEETS(in thousands, except par value, share and per share amounts)As ofAs ofJune 30,September 30,20112010(unaudited)ASSETSCURRENT ASSETS:  Cash and cash equivalents

$
88,226

$
27,081  Amounts due from collaboration partner

-

6  Prepaid expenses and other current assets

2,078

718Total current assets

190,304

127,805EQUIPMENT AND LEASEHOLD IMPROVEMENTS:  Equipment

4,767

4,060  Leasehold improvements

1,836

1,8376,603

5,897  Less accumulated depreciation and amortization

(4,547)

(4,184)Total equipment and leasehold improvements, net

2,056

1,713Restricted cash

100

100Other assets

139

143Total

$
92,599

$
29,761LIABILITIES AND STOCKHOLDERS’ EQUITYCURRENT LIABILITIES:  Current portion of long-term debt

$
3,919

$
8,705  Accounts payable

3,353

5,037  Accrued expenses

6,174

5,863  Deferred rent

27

25  Deferred revenue

985

985Total current liabilities

14,458

20,615  Deferred rent

98

93  Deferred revenue

1,232

1,971  Long-term debt, net of discount of $29 and $150 as of
June 30, 2011 and September 30, 2010, respectively

477

2,934Total liabilities

16,265

25,613Commitments and contingenciesSTOCKHOLDERS' EQUITY:  Common stock, $0.001 par value, 100,000,000 shares authorized,
37,624,362 and 34,043,898 shares issued and outstanding at
June 30, 2011 and September 30, 2010, respectively

38

34  Warrants to purchase 38,727 shares of common stock for
$12.05 per share at June 30, 2011, and 127,248
shares of common stock for $12.05 per share at
September 30, 2010

380

1,230  Additional paid-in capital

475,348

336,351  Accumulated deficit

(299,432)

(233,467)Total stockholders’ equity

176,334

104,148Total

$
92,599

$
29,761
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
2. Pharmasset to Present at Two Upcoming Investor Conferences
3. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
4. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
5. Pharmasset to Webcast an Investor Event From the EASL Meeting
6. Pharmasset to Present at Three Upcoming Investor Conferences
7. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
8. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
9. Pharmasset Announces Exercise of Underwriters Overallotment Option
10. Pharmasset Prices Public Offering of Common Stock
11. Pharmasset Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
Breaking Medicine News(10 mins):